Research

Hormonal

Long-term testosterone therapy (1000 mg testosterone undecanoate every 12 weeks) in hypogonadal men significantly ameliorates metabolic syndrome components, including reducing total cholesterol, LDL, triglycerides, blood glucose, HbA1c, and blood pressure, while increasing HDL.

For hypogonadal men, long-term testosterone therapy (1000mg every 12 weeks) can significantly improve metabolic health markers like cholesterol, blood sugar, and blood pressure, potentially lowering heart disease risk. This should be considered under medical supervision for those with confirmed low testosterone and metabolic syndrome components.

ModerateSupportsMEDIUM confidence
Long-term T therapy, at physiological levels, ameliorates MetS components. These findings strongly suggest that T therapy in hypogonadal men may prove useful in reducing the risk of cardiometabolic diseases.
Abdulmaged M. Traish et al. · International Journal of Clinical Practice · 2013

Why this rating

Observational registry study with no control group; potential confounding by lifestyle changes or concurrent medications not fully controlled.

Source

Long‐term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long‐term registry study

Abdulmaged M. Traish et al. · International Journal of Clinical Practice · 2013

DOI 10.1111/ijcp.12319

cohort · n=255Cited 185×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →